SWOG clinical trial number
S9926

Phase II Study of Temozolomide in Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Closed
Phase
Accrual
56%
Abbreviated Title
Gastrointestinal Stromal Tumor
Activated
04/15/2000
Closed
09/01/2003
Participants
NCORP, Members, Medical Oncologists

Research committees

Sarcoma

Treatment

Temozolomide

Eligibility Criteria Expand/Collapse

Pts must have histologic or cytologic dx of GIST that is unresectable or metastatic. Pts. must have at least one measurable lesion by x-ray, scans (CT or MRI), ultrasound, or physical exam documented 28 days prior to registration. Zubrod PS 0-2. No prior chemo for this dz except for STI-571 as adjuvant therapy or tx for met dz. No prior or concomitant RT except palliative RT. Prior surgery is allowed if at least 4 wks have elapsed and pt has recovered from all side effects. Pts w/ uterin, retroperitoneal sarcomas on non-intraabdominal leioymosarcomas are not eligible.